<DOC>
	<DOC>NCT02357069</DOC>
	<brief_summary>This is a randomized, double-blind, parallel group, multicenter clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of LBEC0101 compared to Enbrel in subjects with active Rheumatoid Arthritis despite Methotrexate therapy.</brief_summary>
	<brief_title>A Study Comparing LBEC0101 to Enbrel® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Male or Female patients from 20 years to 75 years of age when signing Informed Consent. Diagnosed as having RA according to the revised 1987 ACR criteria for at least 6 months prior to screening Patients who have inadequate response to MTX administered for at least 12 weeks before the beginning of screening period and on a stable dose. patients with active tuberculosis or latent tuberculosis based on current clinical symptoms, chest Xray test and IFNγ release assay at screening patients with any of the following concomitant diseases and/or history within 24 weeks before the first administration of investigational products in this study; Serious infectious disease, Opportunistic infection, Chronic or recurrent infectious disease patients with any seropositive result for hepatitis B or hepatitis C or HIV patients who have any of the following diseases; Sepsis, Demyelinating disorders, Lymphoproliferative disease, Infection with prosthetic joint, Autoimmune diseases other than rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>